INTS — Intensity Therapeutics Balance Sheet
0.000.00%
- $8.75m
- $6.16m
Annual balance sheet for Intensity Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 9.32 | 4.54 | 1.31 | 14.8 | 2.59 |
Net Total Receivables | 0.054 | 0.051 | 0.062 | — | — |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 9.63 | 4.73 | 1.45 | 15.5 | 3.36 |
Net Property, Plant And Equipment | 0.49 | 0.318 | 0.139 | 0.147 | 0.122 |
Other Long Term Assets | |||||
Total Assets | 10.1 | 5.22 | 1.76 | 17.3 | 4.78 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Current Liabilities | 1.35 | 3.72 | 6.82 | 3.96 | 1.75 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 1.71 | 3.9 | 6.85 | 4.13 | 1.86 |
Redeemable Preferred Stock | |||||
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 8.44 | 1.32 | -5.1 | 13.2 | 2.92 |
Total Liabilities & Shareholders' Equity | 10.1 | 5.22 | 1.76 | 17.3 | 4.78 |
Total Common Shares Outstanding |